Ophthalmic Biomaterials and Drug Delivery Systems

点击翻译按钮获取中文摘要

Diseases of the eye represent a significant and increasing burden to society. The cost of vision loss in Canada in 2009 was estimated to be $15.8 B; the number of people living with vision loss is currently more than 1M, more than breast cancer, prostate cancer, Alzheimers and Parkinson's disease combined. This number is expected to double over the next 25 years. Not only does eye disease impact the ability to see, it can have a significant effect on quality of life. The ability to effectively deliver drugs has been suggested as the greatest unmet need in ophthalmology. The chair will focus on developing ocular drug delivery materials and surfaces. Using the high throughput synthesis and characterization to generate libraries of materials, Dr. Sheardown will be able to screen large numbers of materials and ultimately develop the next generation of ophthalmic materials.